With Voxzogo under pressure, BioMarin touts trial win in label expansion bid

21st May 2026 Uncategorised 0

With phase 3 results that have “exceeded” BioMarin’s expectations, the California biotech looks set up to gain a label expansion for its top-selling product, dwarfism drug Voxzogo.

More: With Voxzogo under pressure, BioMarin touts trial win in label expansion bid
Source: fierce